Bio Green Med Solution, Inc. (BGMS) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Bio Green Med Solution Inc (BGMS) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, BGMS is a tiny Nasdaq-listed company tied to biotechnology on paper, but right now the stock story is being driven much more by a merger/deal announcement and trading volatility than by a proven profitable operating business. > **📍 Basic Profile** > > Market Cap **$8.28 million** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$1.50** > **⚡ 3 Things You Should Know** > > 1. ⚠️ Business quality looks weak right now: BGMS is deeply unprofitable, with **-117.77% net margin** and **-51.2% ROE**, which basically means the company is losing more than it brings in and has not shown a sustainable earnings model yet. > > 2. 📈 The stock is trading on event excitement, not fundamentals: shares jumped sharply after the announced business combination with Malaysia-based waste tech company Future NRG, so near-term price action may depend more on deal sentiment than on current financial performance. > > 3. 💸 Balance sheet is oddly clean for a weak business: the company shows **no debt** and a very high **current ratio of 7.06**, which gives it breathing room, but cash strength alone does not fix the core issue that operations are still not generating healthy profits. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -117.77%, far below healthy levels | > | Growth Rate | [Data unavailable] | Revenue growth data not provided | > | Financial Health | Healthy💚 | Debt/equity 0, current ratio 7.06 | > | Valuation | Pricey | No PE due to losses; P/S 5.43x for a loss-making micro-cap | ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** [Data unavailable] — the provided data identifies BGMS as a biotechnology company, but does not give a clear segment-level description of products, customers, or revenue model. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Core business segments | [Data unavailable] | [Data unavailable] | No segment disclosure in provided data | | Proposed Future NRG combination | [Not yet applicable] | ↑ | Could materially reshape the business mix if completed | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 18.43% | Below Average | Low gross margin suggests limited pricing power or inefficient cost structure | | Net Margin | -117.77% | Below Average | The company is losing more than $1 for every $1 of revenue | | ROE | -51.2% | Average | Negative and weak | Shareholder capital is not generating returns right now | --- #### 📈 How's the Growth? **Growth Assessment:** [Data unavailable] / Likely unstable | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What’s interesting is that we can’t really call this a healthy growth story from the numbers provided. There’s no usable revenue growth history here, and the recent stock surge appears tied to the merger announcement rather than to clear organic operating momentum. In other words, the market is reacting to a possible future business shape, not strong current execution. --- #### 💰 Financial Health Check **One Sentence:** Think of it like someone with very little debt and plenty of near-term liquidity, but whose paycheck still doesn’t cover monthly spending. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0% debt/equity | <60% safe | ✅Safe | | Current Ratio | 7.06 | >1.5 healthy | ✅Safe | | Cash Flow | [Data unavailable] | >0 | [Data unavailable] | Worth noting, the balance sheet looks much better than the income statement. That matters because it lowers immediate survival risk, but for a micro-cap like this, funding needs can still come back quickly if losses continue. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $0.73 - 52-Week High: $23.22 - Current: $1.50, Near the low | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(3.4% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [N/A] | 5-year avg [Data unavailable] | Loss-making, so PE is not meaningful | | vs Peers | P/S 5.43x | Industry avg [Data unavailable] | Hard to judge precisely, but not obviously cheap for a company with deeply negative margins | **What the Current Valuation is Betting On:** > Basically, the market is betting less on current biotech fundamentals and more on the idea that the Future NRG transaction could give BGMS a new story, new assets, or a more investable business narrative. If that deal disappoints or takes too long, the current excitement could fade fast. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-06-05 | Announced business combination agreement with Future NRG | Positive + This is the main driver behind the recent stock spike and could reshape the company story | | 2026-06-05 | Shares surged after the Malaysia waste-tech acquisition news | Positive / Speculative + Strong momentum, but clearly event-driven rather than fundamentals-driven | | 2026-06-05 | Multiple reports flagged unusual volume and gap-up trading | Neutral + Confirms elevated speculation and volatility | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 18.43% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -117.77% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -51.2% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2024-09-30 | -135.864 | -43.200 | +68.2% Beat 😀 | | 2024-06-30 | -351.288 | -172.800 | +50.8% Beat 😀 | | 2024-03-31 | -1161.576 | -544.800 | +53.1% Beat 😀 | | 2023-12-31 | -1442.687 | -1495.200 | -3.6% Miss 😟 | **Earnings Trend Interpretation:** The interesting part is that BGMS has recently beaten very low earnings expectations for three straight quarters, but the company is still posting big losses. So this is more a case of “less bad than feared” than “actually good.” --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 0 firms | 0% | | Hold | 3 firms | 50% | | Sell | 3 firms | 50% | **Target Price:** [Data unavailable] **vs Current Price:** [Data unavailable] **Insider Activity:** [Data unavailable] in past 3 months > No insider transaction data was provided, so we can’t read management conviction from buying or selling activity here. Worth noting: analyst sentiment seems to have deteriorated sharply. In late 2024, recommendations were much more positive, while the more recent data shows no buys and a split between hold and sell/strong sell. That usually signals confidence has weakened. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Profitability Risk:** The company’s margins are deeply negative and ROE is sharply below zero → If this continues, it could lead to dilution, restructuring, or a need for fresh capital later. 2. **Deal Execution Risk:** The stock is reacting strongly to the Future NRG business combination announcement, but financial terms were undisclosed → If the market dislikes the eventual details or the deal falls through, the share price could give back a lot of the recent gains. 3. **Micro-cap Volatility Risk:** With only about **$8.28 million** in market cap and recent unusual-volume headlines, BGMS can move violently on news flow → That can create upside bursts, but also very sharp drawdowns. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** BGMS is a very small Nasdaq-listed company currently trading more like a special situation than a clean biotech fundamentals story. > > **Key strength:** Its balance sheet appears unusually light on debt and liquid enough to avoid immediate financial stress. > > **Key risk:** The core business is still deeply unprofitable, and the recent rally seems heavily tied to merger speculation rather than proven operating improvement. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis